Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Eton Pharmaceuticals (Nasdaq: ETON) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026.
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT).
Investors may join the participant call or webcast, submit live questions, or email questions to investorrelations@etonpharma.com. An archived webcast will be available on the company investor website approximately two hours after the event and remain for 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ETON
On Mar 4, the first trading day after this news, ETON closed 0.46% above the previous close.
Data tracked by StockTitan Argus for the Mar 4 session.
Key Figures
- Earnings date
- March 19, 2026
- Scheduled Q4 and full-year 2025 results
- Quarter reported
- Fourth quarter 2025
- Period to be discussed on call
- Full year period
- Full year 2025
- Annual results to be reported
- Conference call time ET
- 4:30 p.m. ET
- Start time of results call
- Conference call time CT
- 3:30 p.m. CT
- Central Time start for call
- Webcast archive duration
- 30 days
- Archived webcast availability after event
Historical Context
-
U.S. FDA approval for DESMODA oral solution for central diabetes insipidus.
-
Announcement of participation in Leerink Partners Global Healthcare Conference.
-
Licensing of U.S. rights to an ultra-rare disease product under FDA review.
-
Planned fireside chat at Piper Sandler healthcare conference.
-
Planned one-on-one meetings at Craig-Hallum Alpha Select Conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Participant Call Link: Click Here
Webcast: Click Here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.